Evidence map›Paper›PMID 33708842›Full record

ArticleAnnals of translational medicine2021

Analysis of the differences in lung cancer research trends between China and the United States based using project funding data.

Yuansheng Zheng, Yiwei Huang, Yunyi Bian, Yajing Du, Tao Lu, Qihai Sui, Ming Li, Zhencong Chen, Cheng Zhan, Junjie Xi and 2 more

Abstract read
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuansheng ZhengDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yiwei HuangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yunyi BianDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yajing DuCenter for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Tao LuDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Qihai SuiDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Ming LiDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhencong ChenDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Cheng ZhanDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Junjie XiDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Wei JiangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Qun WangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer is the leading cause of cancer-related death, and countries all over the world have given considerable support to lung cancer research. However, analysis on the status of funding in the field of lung cancer is still lacking.

methodsWe visited the National Natural Science Foundation of China (NSFC) and National Institutes of Health (NIH) official websites to gather lung cancer research information between 2008 and 2020. RSTCM6 software was used to extract the keywords of funded projects which were then imported into CiteSpace software for visual analysis of word frequency.

resultsA total of 1,745 and 5,939 search results were finally obtained from the NSFC and NIH websites, respectively. The amount of NSFC funding for projects in the field of lung cancer increased steadily from 2008 to 2012, while the NIH funding for lung cancer was significantly higher in even years than in odd years between 2008 to 2018. The Shanghai Jiaotong University, Sun Yat-sen University, and Guangzhou Medical University were the top three research institutions that had received the most projects funded by the NSFC. Apoptosis, proliferation, invasion, metabolism, the pathogenesis of lung cancer, cell signal transduction, epithelial-mesenchymal transformation (EMT), and immune-related research were the most frequently funded research areas by the NSFC. Biomarkers, targeted therapy, signal pathway, genomics, and immune-related research were funded most the most frequently funded research areas by the NIH. Both the NIH and NSFC funding for lung cancer immune-related research has increased in recent years.

conclusionsNIH funding in the United States is decreasing year by year, whereas NSFC funding is increasing in China. There are some differences in research focus in lung cancer research funding between China and the United States. However, both countries have increased the support for immune-related research in recent years.

Indexed as

Lung cancerNational Institutes of Health (NIH)National Natural Science Foundation of China (NSFC)research trends

Identifiers

PMID33708842
PMCPMC7940923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.